News

What’s new with DiaSorin Molecular.

Available here is a selection of our latest press releases and news stories.
Filter by year
Published on 12 Jun 2018

DiaSorin Molecular Introduces Primer Pair Reagents for
A. phagocytophilum, Ehrlichia and Babesia

DiaSorin Molecular LLC introduces three new primer pairs for use in laboratory-developed molecular tests. The reagents are specific to three bacterial targets – Anaplasma phagocytophilum, Ehrlichia and Babesia species. These bacteria are commonly carried by ticks. The new offerings join DiaSorin Molecular’s menu of more than 60 molecular reagents for bacterial, viral and fungal targets in addition to human genetic mutations. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory-developed tests (LDTs).


DiaSorin Molecular
Published on 18 Dec 2017

DiaSorin Molecular Launches New Simplexa™ Bordetella Direct Molecular Test

DiaSorin Molecular LLC receives CE Mark for a new Bordetella molecular diagnostic test. Simplexa™ Bordetella Direct is designed to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in human nasopharyngealswabs.


DiaSorin Molecular
Published on 4 Oct 2017

DiaSorin Molecular Introduces Two Primer Pair Reagents for Streptococcus

DiaSorin Molecular introduces two primer pairs – group C and group G Streptococcus – for use in laboratory-developed molecular tests. These new offerings join DiaSorin’s menu of more than 60 molecular reagents for bacterial, viral and fungal targets in addition to human genetic mutations.


DiaSorin Molecular
Published on 26 Sep 2017

DiaSorin Molecular Introduces Primer Pair Reagent for Pneumocystis jirovecii

DiaSorin Molecular announces the expansion of its menu of molecular reagents with the introduction of a P. jirovecii primer pair for use in laboratory-developed molecular tests. (more…)


DiaSorin Molecular
Published on 21 Sep 2017

Extended CE-IVD Certification Expands Sample Claim for DiaSorin Molecular’s Simplexa HSV 1 & 2 Kit

DiaSorin Molecular, LLC announced today that the company has earned CE-IVD certification extending the sample claims for its Simplexa HSV 1 & 2 Direct Assay. The certification adds – cutaneous and mucocutaneous lesion swabs – to previously cleared specimen types of cerebrospinal fluid (CSF) and genital lesion swabs.


DiaSorin Molecular
Published on 12 Sep 2017

DiaSorin Molecular Receives FDA Clearance for Reliable C. difficile Assay on LIAISON® MDX Platform

DiaSorin Molecular today announced the U.S. introduction of the Simplexa® C. difficile Direct Assay, upon receiving clearance from the Food and Drug Administration.

The new assay runs on the company’s LIAISON® MDX system, a scalable benchtop PCR instrument that delivers qualitative and quantitative, sample-to-answer, multi-analyte results. The Simplexa assay detects the Clostridium difficile toxin B gene (tcdB), present in liquid or unformed stool samples, aiding in the diagnosis of C. difficile infection.


DiaSorin Molecular

Events

The upcoming events we are going to take part in.

Discover our Events